来自MSN1 个月
Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527
Prelude’s CEO, Kris Vaddi, Ph.D., emphasized the significance of PRT2527’s results while outlining future priorities. “These findings confirm our hypothesis that a selective and potent CDK9 ...
Nature2 年
New frontiers in ADCs and SMDCs
In addition to VIP236, Vincerx’s pipeline has a clinical-stage cyclin-dependent kinase-9 (CDK9) inhibitor program, VIP152 2, and two preclinical ADC candidates that exemplify the differentiated ...
Yahoo Finance3 年
Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral ...
orally bioavailable cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-amplified solid tumors. “KB-0742 represents a promising new approach to treating cancers that are ...